Araclon Biotech is a company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, currently focusing on Alzheimer’s disease. At present, Araclon is working on four different projects:

The first of these focuses on the diagnosis of Alzheimer’s disease (with a detection kit for beta-amyloid 40 and 42 proteins in blood already patented).

The second is centred on Alzheimer’s therapy (immunotherapy based).

The third is an emerging project, which attempts to respond to the challenge of predicting Alzheimer’s disease in totally asymptomatic individuals.

And finally, a project related to the development of a therapy for the Parkinson’s disease.

 

www.araclon.com

 

CONTACTO:


 


 

 Coordinadora:

Ana Martínez (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Gestora del Proyecto:

Nuria Mª Rivas (This email address is being protected from spambots. You need JavaScript enabled to view it.)

Centro de Investigaciones Biológicas (CIB-CSIC)

C/Ramiro de Maeztu, 9

28006 MADRID

 

 

 

 

 

 

             Proyecto ELA-MADRID.B2017/BMD-3813

 

 Proyecto financiado por la Comunidad de Madrid y la Unión Europea